|
Volumn 11, Issue 5, 2010, Pages 633-636
|
Applying the genome to national drug formulary policy in the developing world
|
Author keywords
Amodiaquine; Essential Medicines List; Global health; PGENI; Pharmacogenetics; Rational therapeutics; WHO
|
Indexed keywords
AMODIAQUINE;
CYTOCHROME P450 2C8;
CLINICAL PRACTICE;
COST BENEFIT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
DECISION MAKING;
DRUG SAFETY;
DRUG SURVEILLANCE PROGRAM;
GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY;
HEALTH CARE;
HEALTH CARE COST;
HEALTH CARE NEED;
HEALTH CARE PERSONNEL;
HEMOLYSIS;
HOMOZYGOSITY;
NOTE;
PATIENT MONITORING;
PHARMACOGENETICS;
POLICY;
POSTMARKETING SURVEILLANCE;
PROCESS OPTIMIZATION;
RISK BENEFIT ANALYSIS;
DELIVERY OF HEALTH CARE;
GENOME;
GENOTYPE;
HUMAN GENOME PROJECT;
HUMANS;
MALE;
PHARMACOGENETICS;
POPULATION GROUPS;
PUBLIC POLICY;
SOCIAL CHANGE;
|
EID: 77951591272
PISSN: 14622416
EISSN: 17448042
Source Type: Journal
DOI: 10.2217/pgs.10.55 Document Type: Note |
Times cited : (21)
|
References (9)
|